Indication Selection

Ready-to-use AI-driven applications to discover and evaluate predicted novel indications for existing therapeutics


Novel indications for existing therapeutics

We work closely with many pharmaceutical & biotech companies to accelerate and de-risk their indication selection process. Euretos' computational, AI-driven disease models predict novel disease associations that domain experts can evaluate rapidly using our AI-integrated knowledge base.

Novel indication predictions from AI-driven, computational disease models
Biomolecular, data-driven approach that minimises potential literature bias
Empowering domain experts to assess results using the Euretos AI Platform
Ready-to-use AI capabilities with rapid onboarding
Indication Selection

Data-driven, novel indication candidates

Euretos computational disease models systematically evaluate gene-disease associations across the whole indication landscape to predict novel indications for a target or therapeutic agent.

eu flag"We have been working with Euretos for many years now. They provide us with unique tools that we use as an integral part of our target discovery and validation. Using the Euretos AI platform is a mandatory input to our target discovery meetings."


Director Target Discovery, Large European Biotech


Indication Selection

Minimise literature bias in indication discovery

To find truly novel indications, we focus on biomolecular and experimental data. By taking into account the indications associated with a target’s biological interaction networks we find yet unexplored disease associations.
Indication Selection

Empower your domain experts to evaluate indication predictions

We provide our client's domain experts access to the Euretos AI Platform to evaluate the predicted indications. Here they can assess key target and disease aspects such as multi-omics interactions, gene expression in tissues, cell types and tumors, pathway interactions, regulatory and signalling responses, gene variants, clinical trials, target tractability and patents.
Enabling world leading pharma, biotech and academic institutions
Janssen and Janssen Pharmaceutical Companies
Leiden Academic Centre for Drug Research
Astra Zeneca
Boehringer Ingelheim
Tufts University
Indication Selection

Rapid onboarding

As our computational disease models and AI-integrated knowledge base are ready-to-use, the onboarding process for new clients is very rapid. In-app tutorials and close support of our translational scientists accelerate the learning curve even further.

Case study

Find out how Euretos helped find novel indications in rare diseases. Submit the below form and get the case study:

SCIENTISTcomlogo     We support purchasing via and science exchange!     Science_Exchange_logo


Enabling world leading pharma, biotech and academic institutions
Logo Daiichi Sankyo
Logo EMC-1
Logo Sanofi-1
Logo LUMC-1

Data-driven disease insights